Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Aretaieion University Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04718116CT.gov Tapentadol Versus Tramadol Analgesia Post Cardiac Surgery | — | Unknown | — | — | — |
NCT01946555CT.gov Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain | — | Completed | — | — | — |
NCT01838616CT.gov Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component. | — | Completed | — | — | — |
NCT01352741CT.gov Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin | — | Completed | — | — | — |
NCT01124617CT.gov A Phase 2 Study of Tapentadol Extended-Release (JNS024ER) ) in Japanese Participants With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia | — | Completed | — | — | — |
NCT00986258CT.gov Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neuralgia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tapentadol (this asset) | Aretaieion University Hospital | Approved | BB · 65 |
| Dexmedetomidine | Universidad Juárez Autónoma de Tabasco | P4 | BBB |
| Midazolam | Minia University | P4 | BBB |
| Lidocaine | Ataturk University | P4 | BBB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Margaux M. Salas, PhD | P4 | BBB |
| Marcaine | Medipol University | P4 | BBB |
| Pregabalin | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | P4 | BBB |
| Capsaicin | University Hospital, Clermont-Ferrand | P4 | BBB |
| Nabilone | Eldon Loh, MD | P4 | BBB |
+42 more in the Neuralgia cohort
Other indications for Tapentadol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Osteoarthritis | — | P4 | BB · 71 |
| Vertebral Column Disorder | — | P4 | BB · 67 |
| Diabetic Neuropathy | — | P3 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tapentadol in Neuralgia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tapentadol-neuralgia-36714
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →